Country: Сингапур
Језик: Енглески
Извор: HSA (Health Sciences Authority)
AZATHIOPRINE
DCH AURIGA SINGAPORE
L04AX01
50 mg
TABLET, FILM COATED
AZATHIOPRINE 50 mg
ORAL
Prescription Only
Excella GmbH & Co. KG
ACTIVE
1988-06-24
IMURAN™ AZATHIOPRINE QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg or 50 mg of the active ingredient azathioprine._ _ Each vial contains 50 mg of the active ingredient azathioprine as the sodium salt. PHARMACEUTICAL FORM Tablet or film-coated tablet. Powder for solution for injection/infusion. CLINICAL PARTICULARS INDICATIONS _IMURAN_ is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. _IMURAN_, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients. _IMURAN_, either alone or more usually in combination with corticosteroids and/or other drugs and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: severe rheumatoid arthritis systemic lupus erythematosus dermatomyositis and polymyositis auto-immune chronic active hepatitis pemphigus vulgaris polyarteritis nodosa auto-immune haemolytic anaemia chronic refractory idiopathic thrombocytopenic purpura DOSAGE AND ADMINISTRATION _IMURAN_ tablets should be administered at least 1 hour before or 3 hours after food or milk (see Pharmacological Properties: Pharm Прочитајте комплетан документ
PROJECT: CR_00009871_COMP_5700759 – Aspen Port Elizabeth DOCUMENT: 5700759 – Aspen Port Elizabeth.pdf DOCUMENT DESCRIPTION: VERSION: 1 VERSION ID: 00002_0000180056 DOWNLOADED: Feb 5, 2024 at 10:42 AM GMT+08:00 BY: LEUNG, JOE (JOE.LEUNG@HK.ASPENPHARMA.COM) APPROVAL STATE: DRAFT IMURAN Azathioprine QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg or 50 mg of the active ingredient azathioprine. Each vial contains 50 mg of the active ingredient azathioprine as the sodium salt. PHARMACEUTICAL FORM Tablet or film-coated tablet. Powder for solution for injection/infusion. CLINICAL PARTICULARS Indications _IMURAN_ is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. _IMURAN_, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients. _IMURAN_, either alone or more usually in combination with corticosteroids and/or other drugs and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: severe rheumatoid arthritis systemic lupus erythematosus dermatomyositis and polymyositis auto-immune chronic active hepatitis pemphigus vulgaris polyarteritis nodosa auto-immune haemolytic anaemia chronic refractory idiopathic thrombocytopenic purpura Dosage and Administration _IMURAN_ tablets should be administered at least 1 hour before or 3 hours after food or milk (see Pharmacological Properties: Pharmacokinetics; Abso Прочитајте комплетан документ